Deals in Depth: June/July 2008
June/July 2008 dealmaking highlights: GSK is banking on insomnia with a $560mm pre-commercial value deal for Actelion's Phase III almorexant; Teva expands its hold on worldwide generics through the $8.7bn purchase of Barr; tying PIPEs for the second-most highest biopharma financing type was the Other category, consisting of TPG-Axon's $300mm investment in Lilly to support AD trials; and late VC money dominates medical device financing, accounting for 45% of the $744mm total.
You may also be interested in...
The European Medicines Agency commits to exploring real-world data as part of its new Regulatory Science Strategy to 2025.
Amgen’s burgeoning biosimilar presence continues to grow apace and now the company has eyes firmly on the US market for eculizumab after brokering a deal with originator Alexion. The biosimilars developer chose to settle on three of Alexion’s patents ahead of a trial later this year.